Pearl III: SVR ≥99% after 12 wks of ABT-450/r/267 + ABT-333 ± RBV in treatment naïve HCV GT1b infection

Authors
Category Primary study
JournalTopics in Antiviral Medicine
Year 2014
This article has no abstract
Epistemonikos ID: 9dacfb729ba95b2bb473b49d3d6a25f8e0264ad2
First added on: Feb 07, 2025